System Requirements


Program Faculty


Faculty Disclosure


Accreditation and Educational Credit


Statement of Educational Need


Educational Objectives


Statement of Evaluation Instrument


Statement of Intended, or Target, Audience


Acknowledgement of Commercial Support
 

References

Listen to Real Audio Round Table Discussion

  1. Neilson EB, Suzdak PD, Anderson KE, et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 1991;196:257-266.


  2. Borden LA, Murali Dhar TG, Smith KE, et al. Tiagabine, SK&F 89976-A, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994;269:219-224.


  3. Meldrum BS, Chapman AG. Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia. 1999;40 (Suppl 9):S2-S6.

  4. Schwartz RD. The GABAA receptor-gated ion channel: Biochemical and pharmacological studies of structure and function. Biochem Pharmacol. 1988;37:3369-3378.

  5. Tecott LH. Designer genes and anti-anxiety drugs. Nature Neurosci. 2000;3(6):529-530.

  6. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor .1 subtype. Nature Neurosci. 2000;3(6):587-592.

  7. Hoffman PL. Glutamate receptors in alcohol withdrawal-induced neurotoxicity. Metab Brain Dis. 1995;10(1):73-79.

  8. al Qatari M, Khan S, Harris B, et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res. 2001;25(9):1276-1283.

  9. Koob GF, Mason BJ, De Witte P, et al. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002;26(4):586-592.

  10. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25(9):1335-1341.

  11. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(Suppl 20): 42-48.

  12. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-1739.

  13. Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17(5): 349-355.

  14. Brady KT, Myrick H, Henderson S, et al. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67(3):323-330.

  15. Rosenthal RN, Perkel C, Singh P, et al. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998;7(3):189-197.

  16. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002; 21(2):55-64.

  17. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry. 1995;152:1399.

  18. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry. 2000;45(1):84.

  19. Chouinard G, Beauclair L, Bélanger M-C. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43(3):305.

  20. Pollack MH, Mathews J, Scott ER. Gabapentin as a treatment for anxiety disorders. Am J Psychiatry. 1998;155(7):992.

  21. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53(Suppl 2):S53-S67.

  22. Bozikas V, Petrikis P, Gamvrula K, et al. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):197-199.

  23. Sheardown MJ, Weis JU, Knutsen LJ. Analgesic effect of the GABA uptake inhibitor NO-328 (N-(4,4-D1(3-methyl-2-thienyl) but-3-1-yl) nipecotic acid). Soc Neurosci Abstr. 1989;15:602.

  24. Freitag FG, Diamond S, Diamond ML, et al. An open use trial of tiagabine in migraine. Headache Q. 2000;11:133-134.

  25. Lancel M, Faulhaber J, Deisz RA. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol. 1998;123:1471-1477.

  26. Gao XM, Kakigi T, Friedman MB, et al. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. J Neurol Transm. 1994;95:63-69.

  27. Holden KR, Titus MO. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol. 1999;21:728-730.

  28. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry. 1998;10:181-184.

  29. Kastberg H, Jansen JA, Cole G, et al. Tiagabine: absence of kinetic or dynamic interactions with ethanol. Drug Metab Drug Interact. 1998;14(4):259-273.

  30. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addiction. 1989;84:1353-1357.

  31. Mathias S, Wetter TC, Steiger A, et al. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging. 2001;22(2):247-253.

  32. Addolorato G, Caputo F, Capristo E, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002; 112(3):226-229.


    Listen to Real Audio Round Table Discussion

[Home]